Cornell dots deliver cancer drugs, diagnostic

Drug delivered: Chemotherapy, diagnostic ability
Innovation: Smallest inorganic drug-delivery nanoparticle
Research organization: Cornell University

Just last month, Cornell professor Ulrich Wiesner, another big innovator in drug-delivering nanotech, made a discovery with his team that resulted in the smallest inorganic drug vehicles yet.

The researchers created a new incarnation of "Cornell dots," or C-dots, which were developed as a small--even by nano standards--diagnostic tool that can pass safely through a patient's urine rather than breaking down in the liver. Drilling a small hole in the C-dots allowed these tiny particles to hold drugs. By combining the diagnostic tool that targets cancer and fluorescently "lights" up tumors with this ability to carry the necessary chemotherapy drugs to the area, they've developed a delivery platform with multiple facets.

Also, Wiesner and his team expect the newest iteration of their nanotech to get to clinical trials relatively easily because it fits into work already done with the same materials.

Cornell dots deliver cancer drugs, diagnostic
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.